20:18 , Jul 7, 2017 |  BC Week In Review  |  Financial News

CIRM awards $44M in grants

The California Institute for Regenerative Medicine awarded more than $44 million over four grants to develop stem cell therapies to treat stroke, a fetal blood disorder and acute myelogenous leukemia (AML). CIRM awarded $20 million...
22:22 , Jun 30, 2017 |  BC Extra  |  Financial News

CIRM awards $44M in grants

The California Institute for Regenerative Medicine awarded more than $44 million over four grants to develop stem cell therapies to treat stroke, a fetal blood disorder and acute myelogenous leukemia (AML). CIRM awarded $20 million...
08:00 , Nov 19, 2015 |  BC Innovations  |  Product R&D

A solid move

Following its IPO in March, Cantargia AB is shifting the focus of its lead program from cancers of the blood to solid tumors. After finding its anti-IL-1RAP mAb affects the tumor microenvironment as well as...
01:01 , Jun 17, 2015 |  BC Extra  |  Company News

Management tracks

The Pharmaceutical Research and Manufacturers of America (PhRMA) elected five new board members. They are Werner Baumann, chairman of the board of management at the Bayer HealthCare AG subsidiary of Bayer AG (Xetra:BAYN); Giovanni Caforio,...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Myeloid Progenitor: Phase II started

Cellerant began an open-label, U.S. Phase II trial to evaluate 2 dose levels of IV CLT-008 given once in combination with daily subcutaneous Neupogen filgrastim in up to 140 patients ages >=55 with de novo...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Clinical News

Myeloid Progenitor: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 49 patients receiving consolidation or induction chemotherapy for leukemia or myelodysplasia showed that a single dose of IV CLT-008 was well tolerated with only 1 dose-limiting toxicity...
07:00 , Oct 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer HER2 (EGFR2; ErbB2; neu) In vitro and mouse studies suggest modified versions of the antibody-drug conjugate trastuzumab-DM1 could help treat breast cancer. The...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

Cellerant, U.S. Department of Health and Human Services cancer, other news

HHS's Biomedical Advanced Research and Development Authority (BARDA) exercised its second option under a 2010 contract and awarded an additional $47.5 million to Cellerant to continue development of CLT-008 for acute myelogenous leukemia (AML). The...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

Cellerant other news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded an additional $36.4 million to Cellerant to continue development of CLT-008 for acute radiation syndrome (ARS). The funding part of a 2010 BARDA five-year contract worth...
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

Cellerant preclinical data

In mice irradiated with lethal doses of radiation, IV allogenic mouse MP cells led to significant, dose-dependent improvements in survival when given up to 7 days post-irradiation vs. vehicle-treated controls. Furthermore, mouse MP cells mitigated...